2nd Circ. Backs Another Eli Lilly Win In Zyprexa MDL

Law360, Chicago (December 10, 2012, 4:41 PM EST) -- The Second Circuit preserved another Eli Lilly & Co. win Monday in a suit in multidistrict litigation alleging it failed to warn about diabetes risks tied to its antipsychotic Zyprexa, finding the two-year time limit on bringing such claims under Virginia law had run out.

In a summary order entered in one of the many appeals stemming from the MDL, a three-judge appeals panel ruled the district court had not erred by finding a former Zyprexa user's claim was barred by a statute of limitations and...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.